Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Challenges in Selecting First-line Therapy for Metastatic Urothelial Carcinoma
  • CME
  • CE

Credits Available
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Registered Nurses: 1.25 Nursing contact hours
Physician Assistants: maximum of 1.25 hours of AAPA Category I (Preapproved) credits
Pharmacists: 1.25 contact hours (0.125 CEUs)
Released: October 19, 2020 Expiration: October 18, 2021
Start Activity
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
NCCN Logo

Karen Kanefield
Manager CE Accreditation & Program Operations
National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
Plymouth Meeting, PA 19462

215-690-0239
215-690-0283 (Fax)
gianola@nccn.org
For Clinicians:
NCCN.org
For Patients:
NCCN.org/patients

Supported by an independent educational grant from Merck & Co., Inc.

Supported by educational grants from
Astellas and Seattle Genetics, Inc.
QED Therapeutics
Matthew I. Milowsky, MD
Daniel P. Petrylak, MD
Jonathan E. Rosenberg, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate checkpoint inhibitor therapies into practice to optimize the care of patients with advanced urothelial carcinoma, considering the available evidence, and patient and disease characteristics
  • Incorporate guideline and expert recommendations to optimally manage adverse events associated with the use of immune checkpoint inhibitors
  • Evaluate biomarkers that accurately predict treatment response and assist in patient selection for personalized therapy
  • Plan therapy for patients with urothelial carcinoma and disease progression during or following platinum-containing chemotherapy and/or immune checkpoint inhibitor therapy
  • Describe the available data and unique mechanisms of action of novel targeted therapies for the treatment of advanced urothelial carcinoma
  • Discuss ongoing clinical trials investigating targeted systemic therapies and ICI-based combinations for patients across the UC disease spectrum

Information on this Educational Activity

Faculty

Matthew I. Milowsky, MD

Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Matthew I. Milowsky, MD, has disclosed that he has received consulting fees from BioClin Therapeutics and funds for research support paid to his institution from Acerta, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cerulean, Clovis, Constellation, Incyte, Innocrin, Inovio, Jounce, MedImmune, Merck, Roche/Genentech, Seattle Genetics, Syndax, and X4 Pharmaceuticals.
Daniel P. Petrylak, MD

Professor of Medicine, Medical Oncology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, Connecticut

Daniel P. Petrylak, MD, has disclosed that he has received consulting fees from Ada Cap (Advanced Accelerator Applications) Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Exelixis, Incyte, Janssen, Lilly, Mirati, Monopteros, Pfizer, Pharmacyclics, Roche, Seattle Genetics, and UroGen; has received funds for research support paid to his institution from Ada Cap (Advanced Accelerator Applications), Agensys, Astellas, AstraZeneca, Bayer, BioXcel, Bristol-Myers Squibb, Clovis, Eisai, Endocyte, Genentech, Innocrin, Lilly, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi, and Seattle Genetics; and has had ownership interests in Bellicum and Tyme.
Jonathan E. Rosenberg, MD

Attending Physician
Chief, Genitourinary Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Jonathan E. Rosenberg, MD, has disclosed that he has received consulting fees from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Merck, Pharmacyclics, Pfizer, Roche/Genentech, and Seattle Genetics; funds for research support from Astellas, AstraZeneca, Bayer, QED Therapeutics, Seattle Genetics, and Roche/Genentech; and faculty honorarium from Chugai.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has disclosed that his spouse/partner has received salary from AstraZeneca and has ownership interest in AstraZeneca.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
NCCN Staff:
Kristina M. Gregory, RN, MSN, OCN, has no relevant conflicts of interest to report.

Lisa Gurski, PhD, has no relevant conflicts of interest to report.

Kristin Kline Hasson, has no relevant conflicts of interest to report.

Karen Kanefield, has no relevant conflicts of interest to report.

Rashmi Kumar, PhD, has no relevant conflicts of interest to report.

Angela Motter, PhD, has no relevant conflicts of interest to report.

Kathy Ann Smith, CHCP, has no relevant conflicts of interest to report.

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). Full disclosure of faculty relationships will be made prior to the activity.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with urothelial cancer.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners to integrate current and emerging therapies into the treatment of patients with urothelial cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

NCCN designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

NCCN designates this educational activity for a maximum of 1.25 contact hour.

Physician Assistant Continuing Education

Credit Designation

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until October 18, 2021. PAs should only claim credit commensurate with the extent of their participation.

Pharmacist Continuing Education

Credit Designation

NCCN designates this application-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN JA4008196-0000-20-107-H01-P

Type of Activity: Knowledge

Attention Pharmacists:
Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 19, 2020, through October 18, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Challenges in Selecting First-line Therapy for Metastatic Urothelial Carcinoma
  • CME
  • CE

Expert review of current options for initial therapy of metastatic urothelial carcinoma.
Matthew I. Milowsky, MD
Daniel P. Petrylak, MD
Jonathan E. Rosenberg, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Registered Nurses: 1.25 Nursing contact hours
Physician Assistants: maximum of 1.25 hours of AAPA Category I (Preapproved) credits
Pharmacists: 1.25 contact hours (0.125 CEUs)
Released: October 19, 2020 Expiration: October 18, 2021

This program is divided into several short segments which you can step through using the Video Chapters menu.
PreviousNext

Related Content

From Clinical Care Options (CCO), expert commentary on key new developments in CAR T-cell therapy and a preview of CAR T-cell data at ASH 2020

Michael Wang, MD Released: December 1, 2020

From Clinical Care Options (CCO), a short video with Kinjal Patel, PharmD, BCOP on use of erdafitinib for patients with advanced or metastatic urothelial carcinoma

person default Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 1, 2020 Expired: November 30, 2021

Dr. John Marshall and Marianne Davies on using TMB to identify patients for checkpoint inhibitors plus challenges with immune-related AEs, from CCO

John L. Marshall, MD Marianne Davies, DNP, CNS, ACNP-BC, AOCNP Released: November 30, 2020

Short video from CCO: Nursing considerations with new therapies for advanced urothelial carcinoma, featuring Susan Roethke, CRNP, MSN, AOCNP, ANP-BC

Susan Roethke, CRNP, MSN, AOCN, ANP-BC Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 30, 2020 Expired: November 29, 2021

Video Chapters


Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
NCCN Logo

Karen Kanefield
Manager CE Accreditation & Program Operations
National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
Plymouth Meeting, PA 19462

215-690-0239
215-690-0283 (Fax)
gianola@nccn.org
For Clinicians:
NCCN.org
For Patients:
NCCN.org/patients

Supported by an independent educational grant from Merck & Co., Inc.

Supported by educational grants from
Astellas and Seattle Genetics, Inc.
QED Therapeutics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue